Scientific Publications

Toxicogenomics is a scientific sub-discipline that combines toxicology with genomics, such as microarray technology. Whether you work at a government or academic research institute, or in the pharmaceutical and biotech industries, Affymetrix solutions can accelerate your toxicology decisions.
Affymetrix offers a complete solution for small molecule and biotherapeutics development. With GeneChip® technology, you can:
- Identify mechanism of toxicity - Find major, specific gene expression changes with biomarkers at the molecular level
- Select compounds and design backup compounds using gene expression
- Reveal species differences in toxicological studies at the molecular level
- Accelerate your toxicological interpretation of gene expression with a ToxFX Report
- Accelerate your throughput and productivity - Run 96 samples at once with Affymetrix' high-throughput solutions
Gold Standard For Toxicogenomics Studies
- The most widely used platform in toxicogenomics research
- The highest number of publications
- Commercial toxicogenomics database support
- Entelos® (previously Iconix)
- Gene Logic®
- High-throughput solutions that allow you to process up to 96 samples at once
- Best annotation tools: The NetAffx® Analysis Center — Get to the biology faster and save time!
Microarray Quality Control (MAQC)
- Highest quality, as demonstrated by the Microarray Quality Control (MAQC) Study
- CV below 5 percent
- Highest correlation to TaqMan® and transcriptional coverage

The Affymetrix Toxicogenomic Platform offers complete species coverage for toxicology, including rat, mouse, canine, rhesus macaque, porcine, zebrafish and human arrays.
Rat Microarrays / Array Plates
Mouse Microarrays / Array Plates
Other Organisms / Array Plates
Human Microarrays / Array Plates

Microarrays as a New Tool for the Toxicologist in Drug Discovery and Development
Abbott's Eric Blomme and Bayer's Heidrun Ellinger-Ziegelbauer discuss toxicogenomics in predictive toxicology, mechanistic toxicology and target selection.
Toxicogenomics Impacts Decision-making Early in the Pipeline at Eli Lilly
Eli Lilly's Tim Ryan discusses using gene expression data to speed development decisions as molecules move through early toxicology assessment.



